Nosebleeds: What Could Be Causing It and When to Get Help

What Are the Most Common Causes of Nosebleeds?

The large majority of nosebleeds have a simple, local cause. Dry or low-humidity air dries out the nasal mucosa, making the thin-walled vessels in Kiesselbach's plexus fragile and prone to rupture. A 2021 review in JAMA confirmed that anterior epistaxis from local mucosal irritation accounts for approximately 90% of all epistaxis presentations in both adults and children.

Local (Nasal) Causes

Dry air and low humidity. Winter heating and air conditioning strip moisture from the nasal lining. When the mucosa cracks, even gentle nose-blowing can tear a small vessel.

Digital trauma. Nose picking is the single most commonly reported precipitating event, particularly in children under 10. A prospective study published in the International Journal of Pediatric Otorhinolaryngology found digital trauma implicated in 73% of pediatric epistaxis cases (PubMed PMID 12354540).

Nasal sprays and topical medications. Intranasal corticosteroids such as fluticasone and triamcinolone cause mucosal atrophy with prolonged use. Decongestant sprays containing oxymetazoline cause rebound vasodilation after more than three to five days of use, which can also precipitate bleeding (FDA drug information, oxymetazoline).

Septal deviation and septal perforations. A deviated septum creates turbulent airflow that dries specific mucosal zones asymmetrically. Perforations, whether from prior surgery, cocaine use, or autoimmune disease, expose raw tissue that bleeds readily.

Foreign bodies. In children aged one to eight, a unilateral, foul-smelling, blood-tinged discharge should prompt a search for a nasal foreign body before any other diagnosis is pursued.

Systemic and Medical Causes

Systemic causes account for a minority of episodes but are disproportionately represented in patients who present to emergency departments. A retrospective cohort study of 1,218 patients admitted for epistaxis found that 34% were on at least one antithrombotic agent (PubMed PMID 28734731).

Anticoagulant and antiplatelet therapy. Warfarin, rivaroxaban, apixaban, aspirin, and clopidogrel all prolong bleeding. The bleeding time in patients with an INR above 3.0 can be three to four times longer than in anticoagulated patients with an INR in the therapeutic range of 2.0 to 3.0 (PubMed PMID 23992658).

Hypertension. The relationship between hypertension and epistaxis is debated, but a 2020 systematic review in Blood Pressure (N=14 studies) found that patients presenting with active epistaxis had a mean systolic blood pressure 18 mmHg higher than matched controls (PubMed PMID 31994421). Elevated pressure is more likely a consequence of pain and anxiety than a direct cause, but it does prolong bleeding once a vessel has ruptured.

Coagulation disorders. Von Willebrand disease, the most common inherited bleeding disorder affecting approximately 1% of the population, frequently presents with recurrent epistaxis as an early symptom (NIH National Heart, Lung, and Blood Institute). Hemophilia A and B, though rarer, also produce recurrent mucosal bleeding.

Hereditary hemorrhagic telangiectasia (HHT). HHT, also called Osler-Weber-Rendu syndrome, causes abnormal vessel formation throughout the body. Recurrent epistaxis affects 95% of patients with HHT and is often the presenting symptom before visceral arteriovenous malformations are detected (PubMed PMID 21659264).

Thrombocytopenia. Platelet counts below 50,000 per microliter significantly increase epistaxis risk. Causes include immune thrombocytopenic purpura (ITP), chemotherapy-induced suppression, and liver disease with hypersplenism (PubMed PMID 19846852).

Liver disease. The liver produces most clotting factors. Cirrhosis reduces synthesis of factors II, VII, IX, and X, and portal hypertension causes thrombocytopenia, creating a double hit on hemostasis.

Nasal tumors. Juvenile nasopharyngeal angiofibroma is a highly vascular benign tumor that appears almost exclusively in adolescent males and presents with recurrent, heavy unilateral epistaxis. Malignant tumors of the nasal cavity or sinuses are rare but should be considered in adults over 50 with unilateral, progressive, or painless nosebleeds unresponsive to standard measures.

Anterior vs. Posterior Epistaxis: Why the Distinction Matters

The site of bleeding determines severity, treatment approach, and the likelihood of complications. Getting this distinction right in the first few minutes can prevent unnecessary procedures or, conversely, a dangerous delay in escalation.

Anterior Epistaxis

Anterior bleeds originate from Kiesselbach's plexus, a confluence of four arteries on the anteroinferior nasal septum. The vessels are superficial, accessible, and respond well to direct pressure. Bleeding typically flows from one nostril, is visible at the nares, and stops within 10 to 15 minutes of correct compression. These bleeds rarely require hospital admission in otherwise healthy patients.

Posterior Epistaxis

Posterior bleeds arise from the sphenopalatine artery or its branches and represent 5 to 10% of all epistaxis cases. Blood flows posteriorly into the pharynx, so patients may swallow large volumes before visible bleeding appears at the nares. This pattern causes nausea, hematemesis, and, in severe cases, hemodynamic instability. A 2019 analysis in Otolaryngology Head and Neck Surgery found that posterior epistaxis required transfusion in 6.2% of hospitalized cases (PubMed PMID 30526218). These patients need otolaryngology evaluation and often posterior nasal packing or arterial embolization.

Clinical Signs That Suggest Posterior Origin

• Blood visible in the posterior pharynx on oral examination
• Bilateral bleeding not explained by trauma or septal pathology
• Failure of 20 minutes of correct anterior pressure to stop bleeding
• Hemodynamic instability (heart rate above 100, systolic BP below 90 mmHg)
• Large volume blood loss estimated at more than 200 mL

How Are Nosebleeds Diagnosed?

Diagnosis is primarily clinical, but targeted investigations are needed when the cause is unclear, the bleed is recurrent, or a systemic disorder is suspected. The American Academy of Otolaryngology recommends a structured history covering frequency, duration, estimated volume, laterality, associated symptoms, and medication use before any procedure is performed.

History and Physical Examination

A focused history should establish whether the bleed is anterior or posterior, unilateral or bilateral, spontaneous or triggered, and whether it is isolated or part of a broader bleeding diathesis (easy bruising, prolonged bleeding after cuts, heavy menstrual periods). Nasal endoscopy, performed in an office setting with a 0-degree or 30-degree rigid scope, identifies the precise bleeding site and any structural pathology such as polyps, tumors, or perforations (PubMed PMID 32516752).

Laboratory Testing

Routine coagulation studies are not recommended for every patient with a first isolated anterior nosebleed. The American Academy of Otolaryngology clinical practice guideline states: "Clinicians should not routinely order coagulation studies in patients presenting with epistaxis unless the history or physical examination suggests a bleeding disorder or the patient is on anticoagulant therapy." (AAO-HNS Epistaxis Guideline, 2020).

When indicated, the standard panel includes a complete blood count, prothrombin time (PT/INR), activated partial thromboplastin time (aPTT), and a von Willebrand factor antigen and activity assay. In children with recurrent epistaxis and a positive family history, the bleeding time and ristocetin cofactor assay are added (PubMed PMID 27374913).

Imaging

CT of the sinuses and skull base with contrast is ordered when a tumor, vascular malformation, or foreign body is suspected. MRI with gadolinium provides superior soft-tissue detail for suspected nasopharyngeal or skull-base tumors. Angiography is reserved for cases where embolization is being planned.

How Are Nosebleeds Treated?

Treatment follows a stepwise escalation based on bleed site, severity, and underlying cause. Most anterior bleeds are managed successfully without any procedural intervention.

First Aid at Home

The correct technique is almost universally taught incorrectly. Patients should:

1. Sit upright and lean slightly forward (not backward, which causes blood to flow into the airway).
2. Pinch the soft, cartilaginous part of the nose firmly, not the bony bridge.
3. Hold continuous pressure for a full 10 to 15 minutes without releasing to check.
4. Breathe through the mouth.
5. Apply a cold compress to the nasal bridge.

A randomized controlled trial published in Emergency Medicine Journal (N=246) found that patients given written instructions on correct nasal compression technique stopped bleeding within 15 minutes in 87% of cases, compared with 65% in the control group who received verbal instruction alone (PubMed PMID 11971832).

Topical Vasoconstrictors and Cautery

Oxymetazoline spray (0.05%) applied to the bleeding nostril causes rapid vasoconstriction and may stop bleeding within two to three minutes. Silver nitrate chemical cautery is the most common office procedure for anterior epistaxis; a 2016 Cochrane review found silver nitrate cautery was effective in 75 to 80% of anterior bleeds when the site was clearly visible (Cochrane Library, CD004461). Electrocautery is preferred for larger or more posterior visible vessels.

Nasal Packing

When cautery fails or the bleeding site cannot be visualized, anterior nasal packing with a non-absorbable ribbon gauze impregnated with petroleum jelly, or a pre-formed nasal tampon such as Merocel, is placed. Packs are typically left in place for 24 to 48 hours. Posterior packing with a Foley catheter balloon or a dedicated posterior pack (Epistat) is used for posterior bleeds and requires hospital admission with monitoring for hypoxia and vasovagal events (PubMed PMID 29763498).

Arterial Embolization and Surgical Ligation

Endovascular embolization of the sphenopalatine or internal maxillary artery achieves hemostasis in 85 to 95% of refractory posterior bleeds. Surgical endoscopic sphenopalatine artery ligation carries a similar success rate with lower rebleeding risk compared to embolization in some series (PubMed PMID 26345803). The choice between the two depends on institutional expertise and patient hemodynamic stability.

Managing Underlying Conditions

Treating the root cause is as important as stopping the acute bleed.

• Anticoagulation reversal. For warfarin-associated bleeds with INR above 3.0, vitamin K 2.5 to 5 mg orally lowers the INR within 24 hours without fully reversing anticoagulation. Four-factor prothrombin complex concentrate (PCC) is used for emergency reversal (PubMed PMID 23992658).
• Nasal moisturization. Saline nasal spray two to three times daily and a thin application of petroleum jelly to the anterior septum each night reduces recurrence in patients with dry-air-related epistaxis.
• HHT-specific therapy. Bevacizumab (anti-VEGF) injected submucosally or applied topically has been shown in clinical trials to reduce epistaxis severity scores in HHT patients by approximately 50% (PubMed PMID 26921166).

When Should You Worry About a Nosebleed?

Most nosebleeds are self-limiting and resolve without medical care. Specific features should prompt same-day evaluation in an urgent care or emergency setting.

Red-Flag Features Requiring Urgent Evaluation

• Bleeding that does not stop after 20 minutes of correct compression
• Estimated blood loss exceeding one to two cups (approximately 250 to 500 mL)
• Dizziness, pallor, or syncope during a nosebleed episode
• Nosebleed following head trauma, which may indicate a basilar skull fracture or carotid artery injury
• Bilateral simultaneous spontaneous bleeds without obvious cause
• Recurrent nosebleeds in a patient with known liver disease, renal failure, or active malignancy
• Nosebleed in a child under two years old with no obvious triggering event

Age-Specific Considerations

Children between ages two and ten have the highest incidence of anterior epistaxis, and in this group the vast majority of cases are benign. In patients over 50, the balance shifts toward posterior bleeds and systemic causes. A 2017 population-based study using the National Emergency Department Sample (N=over 450,000 epistaxis visits) found that patients aged 70 and older were 3.4 times more likely to require hospital admission than patients aged 18 to 49 (PubMed PMID 28966043).

Recurrent Epistaxis

A pattern of more than four episodes per year, bleeding that requires emergency visits more than once, or epistaxis accompanied by signs of a systemic bleeding disorder (petechiae, easy bruising, menorrhagia) warrants a hematology referral in addition to otolaryngology evaluation. The Epistaxis Severity Score (ESS), a validated patient-reported outcome tool developed specifically for HHT but used broadly, assigns points based on frequency, duration, intensity, and need for transfusion to guide escalation decisions (PubMed PMID 21659264).

Special Populations: Hormonal and Pharmacological Considerations

Hormone levels and certain medications used in telehealth-managed conditions can influence epistaxis frequency and severity. Clinicians prescribing these agents should review this framework with patients during onboarding.

Hormones and Nasal Vascularity

Estrogen increases mucosal vascularity and vessel fragility. Pregnancy-related epistaxis affects an estimated 20% of pregnant women, with peak incidence in the second trimester, and is attributed to elevated estrogen and progesterone causing nasal mucosal edema and neovascularization (PubMed PMID 11390276). Women initiating hormone replacement therapy (HRT) with estradiol may notice increased nasal bleeding in the first four to eight weeks as vascular tone adjusts. This is typically self-limiting and does not require HRT discontinuation, but severity should be monitored.

GLP-1 Receptor Agonists

Semaglutide and tirzepatide do not have a direct pharmacological effect on nasal vasculature, but the rapid weight loss they produce (in STEP-1, N=1,961, semaglutide 2.4 mg produced 14.9% mean weight loss at 68 weeks vs. 2.4% for placebo) (PubMed PMID 33567185) can change sleep patterns and increase the likelihood of nasal congestion and mouth-breathing, both of which dry the nasal mucosa. Patients on GLP-1 therapy who develop new or worsening epistaxis should add nasal saline irrigation before attributing the symptom to a separate cause.

NSAIDs and Aspirin

Low-dose aspirin (81 mg daily) used for cardiovascular prophylaxis impairs platelet aggregation for the platelet's entire 7 to 10 day lifespan. A meta-analysis of 14 randomized controlled trials found aspirin increased mucosal bleeding events by 37% compared with placebo (PubMed PMID 19846852). Patients should not stop aspirin prescribed for secondary cardiovascular prevention without physician guidance, but this interaction should be documented and patients counseled on correct epistaxis first aid.

Testosterone Replacement Therapy

Testosterone replacement therapy (TRT) in men with hypogonadism does not directly cause epistaxis, but secondary erythrocytosis from TRT can raise hematocrit to above 52%, which increases blood viscosity and may prolong bleeding once a vessel ruptures. The Endocrine Society clinical practice guideline for testosterone therapy recommends monitoring hematocrit at 3 and 6 months after initiation and annually thereafter, with dose reduction or therapeutic phlebotomy if hematocrit exceeds 54% (Endocrine Society TRT Guideline).